



Prime Medicine to Present at Investor Conferences in June

May 31, 2023

CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in three investor conferences in June:

- **Jefferies Healthcare Conference:** Fireside chat on Wednesday, June 7, 2023 at 10:00 a.m. ET in New York, NY.
- **Goldman Sachs Global Healthcare Conference:** Fireside chat on Monday, June 12, 2023 at 1:20 p.m. PT (4:20 p.m. ET) in Dana Point, CA.
- **2023 Truist Securities symposia-cel:** Panel discussion titled "In Vivo Cell Therapy Through Targeted Delivery and Editing" on Tuesday, June 27, 2023 at 3:00 p.m. ET in New York, NY.

Live audio webcasts of the Jefferies and Goldman Sachs fireside chats will be available under "Events & Presentations" in the News & Events section of the Company's website at www.primemedicine.com. Replays of the webcasts will be available on the Prime Medicine website for 30 days following the presentation.

About Prime Medicine

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types.

Prime Medicine is currently progressing a diversified portfolio of eighteen programs initially focused on genetic diseases with a fast, direct path to treating patients or with a high unmet need because they cannot be treated using other gene-editing approaches. Over time, the Company intends to maximize Prime Editing's therapeutic potential and advance potentially curative therapeutic options to patients for a broad spectrum of diseases. For more information, please visit www.primemedicine.com.

Investor Contact

Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media Contact

Dan Budwick, 1AB
dan@1ABmedia.com